Culture Biosciences Appoints Mike Stapleton To Board As It Expands Stratyx Hardware And Console SaaS Platform

Culture Biosciences, a company known for its cloud-connected bioprocess development technologies, has announced the appointment of Mike Stapleton to its Board of Directors. His addition comes at an important time as the company continues to expand its Stratyx hardware platform and grow its Console SaaS offering.

Mike Stapleton brings more than three decades of experience in the life sciences sector, with a strong background in instruments, software commercialization, and biopharmaceuticals. His expertise closely matches Culture Biosciences’ current strategic priorities, particularly as the company focuses on scaling its technology platforms and strengthening its presence in the market.

This appointment is part of a planned transition in the company’s governance structure following its Series C financing completed in the fall. As part of this transition, Stapleton takes over a board position previously held by Independent Director Beth Webb. After completing her two-year term, Webb will continue her association with the company as a Strategic Advisor. Culture Biosciences acknowledged her valuable guidance during a key phase of its growth.

In addition, the company’s co-founder, Will Patrick, has stepped down from the Board as part of this transition. His leadership and vision have been instrumental since founding the company in 2016, and the organization expressed its appreciation for his long-standing contributions.

Chris Williams, Chief Executive Officer of Culture Biosciences, stated that the changes to the Board are designed to align the company with the expertise needed for its next phase of growth. He highlighted Stapleton’s extensive experience in bringing life science instruments and software solutions to global markets, noting that his insights will support the company as it advances commercialization efforts and continues to develop its AI-driven capabilities through its Console platform.

Mike Stapleton currently serves as Chief Business Officer at QbDVision and is widely recognized as a seasoned leader in the life sciences industry. Throughout his career, he has held senior leadership roles across several major organizations. These include serving as Vice President and Chief Information Officer of R&D IT at Merck, General Manager of Informatics at PerkinElmer, Vice President of Informatics at Life Technologies, Executive Vice President and Chief Operating Officer at Accelrys, and Managing Director of Life Sciences at Accenture.

His professional experience spans a wide range of areas, including software, laboratory instruments, consumables, services, and pharmaceuticals. He is particularly known for his work in digital transformation, commercialization of life science software, and building scalable platforms that integrate data and biology.

Commenting on his new role, Stapleton said that Culture Biosciences has developed a distinctive platform that combines hardware and software in a way that addresses key challenges in bioprocess development. He expressed enthusiasm about joining the Board and contributing to the company’s efforts to expand its reach and bring its technology to a broader market. With this leadership update, Culture Biosciences aims to strengthen its strategic direction and accelerate growth as it continues to innovate in the bioprocess development space.